Rinri Therapeutics

Rinri Therapeutics

Private
SheffieldHealthcare & Life Scienceshttps://rinri-therapeutics.com

Last Round

Grant

Oct 2, 2025

Total Funding Raised

$41.2M

Momentum Score

25 /100

Company Overview

Rinri Therapeutics is a biotechnology company developing first-in-class cell therapies to restore hearing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

cell therapyregenerative medicinehearing restorationsensorineural hearing lossSNHLstem cell therapyauditory neuron replacementallogeneic cell therapyoff-the-shelf cell therapyotic neural progenitor cellsauditory neuropathyage-related hearing losscochlear implantcell and gene therapyCGThair cell replacement

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rinri Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Rinri Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantOct 2, 2025
Series AJan 14, 2025
Convertible DebtApr 20, 2021
SeedMay 20, 2019

Key People

Founding team and executive leadership

Simon Chandler

CEO And Director

Executive Team

Terri Gaskell

Chief Technology Officer

Executive Team

Rinri Therapeutics Investors

Notable investors and investment history

InvestorRounds
UCB VenturesConvertible Debt, Series A, Seed
Pioneer GroupSeries A
Future Fund (UK Government)Convertible Debt
J.P. Morgan Asset ManagementGrant
Boehringer Ingelheim Venture FundConvertible Debt, Series A, Seed
The University of SheffieldSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 2, 2025

    $1M grant received.

  • Oct 2, 2025

    Attended the 2nd Annual Life Sciences Innovation Summit on October 2, 2025.

Rinri Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Rinri Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Rinri Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSheffield
Employee Range18
Year Founded2018
Last FundingOct 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.